Best Practices for Parental Consent and Minor Assent in Pediatric Research

Regulatory Expectations for Consent and Assent

In pediatric clinical research, two separate but complementary processes are essential: parental consent and minor assent. Parental consent is the legally required authorization from a child’s parent or legal guardian, while minor assent is the child’s affirmative agreement to participate, provided in language they can understand. The ICH E6(R2) Good Clinical Practice guidelines and country-specific regulations (e.g., 21 CFR Part 50 Subpart D in the U.S., EU Clinical Trials Regulation No 536/2014) clearly outline when and how these must be obtained.

Regulatory authorities require that informed consent is obtained before any trial-related activities begin, and that assent is sought when the child is capable of providing it. This is typically from age 7 onwards in the U.S., though the threshold varies globally — in the UK it is often considered at age 10–12, and in Japan it may be earlier depending on cognitive capacity.

Differences Between Consent and Assent

It’s important to note that if a child dissents, many ethics committees recommend honoring that choice unless participation is necessary for the child’s own medical benefit.

Challenges in Obtaining Consent and Assent

Conducting pediatric trials often involves complex scenarios:

• Cross-border trials: Different age thresholds and language requirements.
• Cultural differences: In some communities, children are rarely involved in decision-making.
• Literacy issues: Both parents and children may have low literacy levels, requiring verbal or pictorial explanations.
• Re-assent needs: In long-term trials, children may age into greater understanding, requiring an updated assent process.

Case Study: In a global vaccine trial, one country required assent at age 7, another at age 12, and another mandated only parental consent. The sponsor developed three assent templates to address these differences while maintaining core protocol alignment.

Inspection Observations and Common Deficiencies

Regulatory inspections by agencies like the FDA, EMA, and WHO have highlighted frequent issues:

• Missing assent documentation in eligible participants.
• Consent forms signed after the first study procedure.
• Use of overly complex language in child assent forms.
• No documented process for confirming the child’s understanding.

Example: An EMA inspection of a pediatric asthma trial found that 40% of assent forms were signed on the same day as complex diagnostic tests, raising concerns about adequate reflection time.

Root Causes of Non-Compliance

Several systemic factors contribute to consent/assent non-compliance:

1. Training gaps: Site staff not fully aware of local legal requirements for assent.
2. Template deficiencies: Forms not designed for different literacy or age groups.
3. Process shortcuts: Rushed enrollments leading to incomplete documentation.
4. Inadequate monitoring: Lack of checks for consent/assent completeness before randomization.

Addressing these root causes requires structured SOPs, training, and monitoring integration.

Preventive Strategies for Compliance

To ensure compliance and protect participant rights, sponsors and sites should:

• Develop age-specific assent templates reviewed by child development specialists.
• Implement dual-language forms for bilingual communities.
• Use comprehension quizzes for both parents and children.
• Integrate consent/assent verification into monitoring checklists.

Resources like PharmaSOP.in provide customizable SOP templates for consent/assent processes, aligning with global GCP requirements.

CAPA Approaches for Identified Gaps

When deficiencies are identified, effective Corrective and Preventive Actions (CAPA) should include:

• Corrective: Immediate re-consent/re-assent, update of TMF records.
• Preventive: SOP revisions, targeted re-training, inclusion of age-specific content in consent review meetings.

Regulators expect CAPA to be measurable, with follow-up checks confirming ongoing compliance.

Case Example: Digital Consent and Assent System

In a multi-country pediatric oncology study, the sponsor implemented a digital platform with videos, animations, and interactive comprehension checks for assent. Parental consent was captured via e-signature, and the child could “pause” to ask questions. This approach resulted in 99% documented compliance across 12 countries and was cited as a model practice in an EMA feedback letter.

Conclusion

Managing parental consent and minor assent requires balancing legal compliance with respect for the child’s autonomy. By implementing age-appropriate tools, culturally sensitive processes, and strong documentation practices, sponsors can meet both regulatory and ethical obligations while enhancing participant engagement.